Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and PD of SAR438544 in Healthy Subjects and T1DM Patients
NCT02625636Phase 1Completed
- Sponsor
- Sanofi
- Start
- Dec 2015
- Primary completion
- Feb 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SAR438544 in type 1 diabetes mellitus (T1D) (6 arms), sponsored by Sanofi. Primary endpoint: Number of patients with adverse events. Started Dec 2015; status: completed.
02
Drugs
SAR438544
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02625636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02625636.